APA (7th ed.) Citation

JS, K., SF, T., G, K., M, P., GBE, J., K, G., . . . S, S. (2026). Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study. Journal of the European Academy of Dermatology and Venereology : JEADV. https://doi.org/10.1111/jdv.70594

Chicago Style (17th ed.) Citation

JS, Kern, et al. "Safety and Pharmacokinetics of Anumigilimab for Hidradenitis Suppurativa or Palmoplantar Pustulosis: A Phase 1b Study." Journal of the European Academy of Dermatology and Venereology : JEADV 2026. https://doi.org/10.1111/jdv.70594.

MLA (9th ed.) Citation

JS, Kern, et al. "Safety and Pharmacokinetics of Anumigilimab for Hidradenitis Suppurativa or Palmoplantar Pustulosis: A Phase 1b Study." Journal of the European Academy of Dermatology and Venereology : JEADV, 2026, https://doi.org/10.1111/jdv.70594.